Autolus Therapeutics (AUTL) Reports Q4 Loss of $0.52
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vineti Reports Strategic Partnership with Autolus Therapeutics (AUTL) to Support Delivery of Novel-T Cell Therapies
February 25, 2019 6:25 AM ESTVineti Inc, the leading software platform of record for personalized therapeutics, today announced a new partnership to help advance and scale Autolus Therapeutics plc (NASDAQ: AUTL)s broad clinical stage pipeline of cancer treatments for hematological and solid tumors.
Autolus, a clinical-stage global biopharmaceutical company developing next-generation programmed T cell therapies, has four clinical programs in five hematological and one solid tumor indication. Vineti provides the leading software platform... More
